Rigosertib ameliorates the effects of oncogenic KRAS signaling in a murine model of myeloproliferative neoplasia

Aberrant signaling triggered by oncogenic or hyperactive RAS proteins contributes to the malignant phenotypes in a significant percentage of myeloid malignancies. Of these, juvenile myelomonocytic leukemia (JMML), an aggressive childhood cancer, is largely driven by mutations in RAS genes and those...

Descripción completa

Detalles Bibliográficos
Autores principales: Baker, Stacey J., Cosenza, Stephen C., Ramana Reddy, M.V., Premkumar Reddy, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443005/
https://www.ncbi.nlm.nih.gov/pubmed/30956775
http://dx.doi.org/10.18632/oncotarget.26735

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443005/
https://www.ncbi.nlm.nih.gov/pubmed/30956775
http://dx.doi.org/10.18632/oncotarget.26735

Ejemplares similares